STOCK MARKET BSE NSE

Covid vaccine: Biological E gets nod for Phase-III trials

The trials were conducted on about 360 healthy subjects in the age group of 18- 65 years.

Published: 25th April 2021 09:10 AM  |   Last Updated: 25th April 2021 09:10 AM   |  A+A-

A medical worker prepares to inoculate person with a dose of COVID vaccine (Photo | PTI)

By Express News Service

HYDERABAD: Another  Hyderabad-based pharmaceutical company developing a Covid-19 vaccine, Biological E Limited, has received the approval to conduct Phase-III clinical trials for its vaccine from the Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee.

This was announced in a press release by the company on Friday The company completed the Phase I/ II clinical trials of its Covid-19 subunit vaccine candidate in India, which began in the second week of November, 2020. The trials were conducted on about 360 healthy subjects in the age group of 18- 65 years.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp